Resonance Health Ltd (AU:RHT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Resonance Health Ltd has secured a significant contract worth approximately AUD $13.775 million with Sun Pharmaceutical Industries for a clinical drug trial in Australia. This agreement highlights Resonance’s strategic focus on expanding its presence in the global clinical trials market by providing comprehensive services, including imaging analysis and site management. The contract is expected to boost Resonance’s revenue over the next two years, reflecting its ability to win repeat business and scale its operations.
For further insights into AU:RHT stock, check out TipRanks’ Stock Analysis page.